{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078600","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.654389+00:00","generated_at":"2026-05-31T22:38:27.706560+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics completes MAD dosing for GT-02287 Phase 1; no SAEs, on track for Q4 2024 patient trial","bullets":["Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.","GT-02287 well tolerated up to highest planned dose; 90% of adverse events mild, 10% moderate, no Grade 3+ events.","Topline data expected mid-August after database lock; full safety and PK data to be presented at future congress.","On track to initiate clinical trial in Parkinson's disease patients by Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078600","json":"https://secwatch.observer/filing/0001104659-24-078600.json","markdown":"https://secwatch.observer/filing/0001104659-24-078600.md","text":"https://secwatch.observer/filing/0001104659-24-078600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/0001104659-24-078600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/tm2419145d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:38:27.706560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}